Gunnar Thorsén
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gunnar Thorsén has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Tran Thi Thuy
Department of Analytical Chemistry, Stockholm University, 10691, Stockholm, Sweden
4 shared publications- Jonas Bergquist
Department of Chemistry, Biomedical Centre, Uppsala University, Uppsala, Sweden
2 shared publications Anita Westlind-Danielsson
Department of Analytical Chemistry, Stockholm University, SE-106 91 Stockholm, Sweden, Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Sahlgrenska University Hospital, Mölndal, Sweden, Institute of Chemistry, Department of Analytical Chemistry, Uppsala University, SE-751 21 Uppsala, Sweden, and Bioscience, Discovery RA, CNS & Pain Control, AstraZeneca, SE-151 85 Södertälje, Sweden
1 shared publicationBjörn Josefsson
Department of Analytical Chemistry, Stockholm University, SE-106 91 Stockholm, Sweden, Institute of Clinical Neuroscience, Department of Psychiatry and Neurochemistry, Göteborg University, Sahlgrenska University Hospital, Mölndal, Sweden, Institute of Chemistry, Department of Analytical Chemistry, Uppsala University, SE-751 21 Uppsala, Sweden, and Bioscience, Discovery RA, CNS & Pain Control, AstraZeneca, SE-151 85 Södertälje, Sweden
1 shared publicationErik Tengstrand
1 shared publicationGunnar Ekstrand
Department of Analytical Chemistry, Stockholm University, SE-106 91 Stockholm, Sweden
1 shared publication
Latest Publications
- 30 April 2013
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 24 (7) , 1053-1063
Glycosylation Profiling of Therapeutic Antibodies in Serum Samples Using a Microfluidic CD Platform and MALDI-MS
The serum clearance rate of therapeutic antibodies is important as it affects the clinical efficacy, required dose, and dose frequency. The glycosylation of antibodies has in some studies been shown to have an impact on the elimination rates in vivo. Monitoring changes to the glycan profiles in pharmacokinetics studies can reveal whether the clearance rates of the therapeutic antibodies depend on the different glycoforms, thereby providing useful information for improvement of the drugs. In this paper, a novel method for glycosylation analysis of therapeutic antibodies in serum samples is presented. A microfluidic compact-disc (CD) platform in combination with MALDI-MS was used to monitor changes to the glycosylation profiles of samples incubated in vitro. Antibodies were selectively purified from serum using immunoaffinity capture on immobilized target antigens. The glycans were enzymatically released, purified, and finally analyzed by MALDI-TOF-MS. To simulate changes to glycan profiles after administration in vivo, a therapeutic antibody was incubated in serum with the enzyme α1-2,3 mannosidase to artificially reduce the amount of the high mannose glycoforms. Glycan profiles were monitored at specific intervals during the incubation. The relative abundance of the high mannose 5 glycoform was clearly found to decrease and, simultaneously, that of high mannose 4 increased over the incubation period. The method can be performed in a rapid, parallel, and automated fashion for glycosylation profiling consuming low amounts of samples and reagents. This can contribute to less labor work and reduced cost of the studies of therapeutic antibodies glycosylation in vitro and in vivo. Figure ᅟ
- 30 April 2013
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 24 (7) , 1053-1063
Glycosylation Profiling of Therapeutic Antibodies in Serum Samples Using a Microfluidic CD Platform and MALDI-MS
The serum clearance rate of therapeutic antibodies is important as it affects the clinical efficacy, required dose, and dose frequency. The glycosylation of antibodies has in some studies been shown to have an impact on the elimination rates in vivo. Monitoring changes to the glycan profiles in pharmacokinetics studies can reveal whether the clearance rates of the therapeutic antibodies depend on the different glycoforms, thereby providing useful information for improvement of the drugs. In this paper, a novel method for glycosylation analysis of therapeutic antibodies in serum samples is presented. A microfluidic compact-disc (CD) platform in combination with MALDI-MS was used to monitor changes to the glycosylation profiles of samples incubated in vitro. Antibodies were selectively purified from serum using immunoaffinity capture on immobilized target antigens. The glycans were enzymatically released, purified, and finally analyzed by MALDI-TOF-MS. To simulate changes to glycan profiles after administration in vivo, a therapeutic antibody was incubated in serum with the enzyme α1-2,3 mannosidase to artificially reduce the amount of the high mannose glycoforms. Glycan profiles were monitored at specific intervals during the incubation. The relative abundance of the high mannose 5 glycoform was clearly found to decrease and, simultaneously, that of high mannose 4 increased over the incubation period. The method can be performed in a rapid, parallel, and automated fashion for glycosylation profiling consuming low amounts of samples and reagents. This can contribute to less labor work and reduced cost of the studies of therapeutic antibodies glycosylation in vitro and in vivo. Figure ᅟ
- 21 December 2010
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 399 (4) , 1601-1611
High-throughput profiling of N-linked oligosaccharides in therapeutic antibodies using a microfluidic CD platform and MALDI-MS
- 21 December 2010
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 399 (4) , 1601-1611
High-throughput profiling of N-linked oligosaccharides in therapeutic antibodies using a microfluidic CD platform and MALDI-MS
- 15 October 2010
- Published by Elsevier in Journal of Chromatography B
- Vol. 878 (28) , 2803-2810
Parallel sample preparation of proteins, from crude samples to crystals ready for MALDI-MS, in an integrated microfluidic system
- 15 October 2010
- Published by Elsevier in Journal of Chromatography B
- Vol. 878 (28) , 2803-2810
Parallel sample preparation of proteins, from crude samples to crystals ready for MALDI-MS, in an integrated microfluidic system
- 1 June 2009
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 20 (6) , 1207-1213
SALDI-MS Signal enhancement using oxidized graphitized carbon black nanoparticles
- 1 June 2009
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 20 (6) , 1207-1213
SALDI-MS Signal enhancement using oxidized graphitized carbon black nanoparticles
- 26 April 2001
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 73 (11) , 2625-2631
Stereoselective Determination of Amino Acids in β-Amyloid Peptides and Senile Plaques
A novel method for the determination of the enantiomeric composition of peptides is presented. In this paper, the focus has been on β-amyloid peptides from deceased Alzheimer's disease patients. The peptides are hydrolyzed using mineral acid. The free amino acids are derivatized with the chiral reagent (+)- or (−)-1-(9-anthryl)-2-propyl chloroformate and subsequently separated using micellar electrokinetic chromatography (MEKC) and detected using laser-induced fluorescence (LIF) detection. The high separation efficiency of the MEKC-LIF system, yielding ∼1 million theoretical plates/m for most amino acids, facilitates the simultaneous chiral determination of nine amino acids. The samples that have been analyzed were standard 1−40 β-amyloid peptides, in vitro precipitated β-amyloid fibrils, and human senile plaque samples.
- 26 April 2001
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 73 (11) , 2625-2631
Stereoselective Determination of Amino Acids in β-Amyloid Peptides and Senile Plaques
A novel method for the determination of the enantiomeric composition of peptides is presented. In this paper, the focus has been on β-amyloid peptides from deceased Alzheimer's disease patients. The peptides are hydrolyzed using mineral acid. The free amino acids are derivatized with the chiral reagent (+)- or (−)-1-(9-anthryl)-2-propyl chloroformate and subsequently separated using micellar electrokinetic chromatography (MEKC) and detected using laser-induced fluorescence (LIF) detection. The high separation efficiency of the MEKC-LIF system, yielding ∼1 million theoretical plates/m for most amino acids, facilitates the simultaneous chiral determination of nine amino acids. The samples that have been analyzed were standard 1−40 β-amyloid peptides, in vitro precipitated β-amyloid fibrils, and human senile plaque samples.
- 21 August 2000
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 745 (2) , 389-397
Chiral separation of amino acids in biological fluids by micellar electrokinetic chromatography with laser-induced fluorescence detection
- 21 August 2000
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 745 (2) , 389-397
Chiral separation of amino acids in biological fluids by micellar electrokinetic chromatography with laser-induced fluorescence detection